1. Home
  2. MESO vs SKE Comparison

MESO vs SKE Comparison

Compare MESO & SKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • SKE
  • Stock Information
  • Founded
  • MESO 2004
  • SKE 1979
  • Country
  • MESO Australia
  • SKE Canada
  • Employees
  • MESO N/A
  • SKE N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • SKE Precious Metals
  • Sector
  • MESO Health Care
  • SKE Basic Materials
  • Exchange
  • MESO Nasdaq
  • SKE Nasdaq
  • Market Cap
  • MESO 1.3B
  • SKE 1.4B
  • IPO Year
  • MESO N/A
  • SKE N/A
  • Fundamental
  • Price
  • MESO $11.06
  • SKE $16.31
  • Analyst Decision
  • MESO Buy
  • SKE
  • Analyst Count
  • MESO 4
  • SKE 0
  • Target Price
  • MESO $18.00
  • SKE N/A
  • AVG Volume (30 Days)
  • MESO 213.0K
  • SKE 497.4K
  • Earning Date
  • MESO 08-28-2025
  • SKE 08-07-2025
  • Dividend Yield
  • MESO N/A
  • SKE N/A
  • EPS Growth
  • MESO N/A
  • SKE N/A
  • EPS
  • MESO N/A
  • SKE N/A
  • Revenue
  • MESO $5,670,000.00
  • SKE N/A
  • Revenue This Year
  • MESO $178.09
  • SKE N/A
  • Revenue Next Year
  • MESO $305.06
  • SKE N/A
  • P/E Ratio
  • MESO N/A
  • SKE N/A
  • Revenue Growth
  • MESO N/A
  • SKE N/A
  • 52 Week Low
  • MESO $5.78
  • SKE $5.63
  • 52 Week High
  • MESO $22.00
  • SKE $16.45
  • Technical
  • Relative Strength Index (RSI)
  • MESO 50.02
  • SKE 64.74
  • Support Level
  • MESO $10.32
  • SKE $14.92
  • Resistance Level
  • MESO $10.86
  • SKE $16.15
  • Average True Range (ATR)
  • MESO 0.35
  • SKE 0.70
  • MACD
  • MESO 0.00
  • SKE -0.05
  • Stochastic Oscillator
  • MESO 45.04
  • SKE 91.93

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About SKE Skeena Resources Limited

Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.

Share on Social Networks: